血清 TSGF 和 miR-214 水平在肝癌患者中的变化及其对经导管动脉化疗栓塞疗效的预测价值。

Serum TSGF and miR-214 levels in patients with hepatocellular carcinoma and their predictive value for the curative effect of transcatheter arterial chemoembolization.

机构信息

Department of General Surgery, Chang'an Hospital of Xi'an, Xi'an, China.

Department of Tumor Thoracic Surgery, Hanzhong City People's Hospital, Hanzhong, China.

出版信息

Ann Palliat Med. 2020 Jul;9(4):2111-2117. doi: 10.21037/apm-20-1224.

DOI:10.21037/apm-20-1224

PMID:32762227

Abstract

BACKGROUND

The purpose of this study is to evaluate the expression of tumor-specific growth factor (TSGF) and microRNA-214 (miR-214) in the serum of patients with primary hepatocellular carcinoma (PHC) and their predictive values for the curative effect of transcatheter arterial chemoembolization (TACE).

METHODS

A retrospective analysis of the clinical data of 87 PHC patients were treated with TACE. According to the curative effect 1 month after TACE, PHC patients were divided into disease control group (n=56) and disease progression group (n=31). The expression levels of TSGF and miR-214 were detected by qRT-PCR before or after treatment with TACE in disease control group and disease progression group. The predictive value of TSGF and miR-214 for the efficacy of TACE were evaluated by the receiver operating characteristic (ROC) curve. The Kaplan-Meier survival curve was drawn according to the critical value of ROC. The effect of pretreatment levels of TSGF and miR-214 was analyzed on the three-year survival rate of patients.

RESULTS

After TACE treatment, the mRNA expressive of serum TSGF were increased in progression group, while the levels of miR-214 were decreased compared with control group (P<0.05). Importantly, at one month after TACE treatment, the levels of TSGF were decreased in control group and progression group, while the expression of miR-214 was increased compared with in both groups before TACE treatment(P<0.05). The result of ROC analysis showed that for predicting the curative effect of TACE, the levels of TSGF and miR-214 expression were (181.32, 0.63) (0.849 and 0.807) and (0.759-0.938, 0.707-0.907) in the cutoff values, AUCs and 95% confidence intervals, respectively. The result of Kaplan-Meier analysis showed that the 3-year survival rate of the low TSGF group was up-regulated than that of the high TSGF group [65.12% (31/44) vs. 30.23% (13/43); χ2=5.014; P=0.025]. The 3-year survival rate of the miR-214 high expression group was up-regulated than that of the miR-214 low expression group [61.70% (29/47) vs. 30.00% (12/40); χ2=6.928; P=0.008].

CONCLUSIONS

Serum TSGF and miR-214 could be used as potential biomarkers for PHC diagnosis and prognosis.

摘要

背景

本研究旨在评估肿瘤特异性生长因子（TSGF）和 microRNA-214（miR-214）在原发性肝细胞癌（PHC）患者血清中的表达及其对经导管动脉化疗栓塞（TACE）疗效的预测价值。

方法

回顾性分析 87 例接受 TACE 治疗的 PHC 患者的临床资料。根据 TACE 后 1 个月的疗效，将 PHC 患者分为疾病控制组（n=56）和疾病进展组（n=31）。采用 qRT-PCR 检测疾病控制组和疾病进展组 TACE 前后 TSGF 和 miR-214 的表达水平。采用受试者工作特征（ROC）曲线评估 TSGF 和 miR-214 对 TACE 疗效的预测价值。根据 ROC 的临界值绘制 Kaplan-Meier 生存曲线。分析预处理 TSGF 和 miR-214 水平对患者 3 年生存率的影响。

结果

TACE 治疗后，进展组血清 TSGF mRNA 表达升高，而 miR-214 水平降低与对照组比较（P<0.05）。重要的是，TACE 治疗后 1 个月，两组 TSGF 水平均降低，而两组 miR-214 表达均高于 TACE 治疗前（P<0.05）。ROC 分析结果表明，预测 TACE 疗效时，TSGF 和 miR-214 表达的截断值分别为（181.32、0.63）、（0.849 和 0.807）和（0.759-0.938、0.707-0.907），AUC 及其 95%置信区间分别为（0.815-0.877）和（0.759-0.877）。Kaplan-Meier 分析结果表明，低 TSGF 组的 3 年生存率高于高 TSGF 组[65.12%（31/44）比 30.23%（13/43）；χ2=5.014；P=0.025]。miR-214 高表达组的 3 年生存率高于 miR-214 低表达组[61.70%（29/47）比 30.00%（12/40）；χ2=6.928；P=0.008]。